[ET Net News Agency, 16 July 2021] HSBC Global Research lowered its target price for JD
Health (06618) to HK$149 from HK$154 and maintained its "buy" rating.
The research house said it lifts its top line estimate for FY21e by 4%, but lower its
FY21e/22e/23e net profit estimates by 37%/27%/33% respectively, after factoring in the
company's investment plans in the next three years. (RC)